Skip to main content
Wiley Open Access Collection logoLink to Wiley Open Access Collection
. 2026 Jul 27;52(8):e70419. doi: 10.1111/jog.70419

Managing Pregnancy in Inherited Metabolic Disorders: Experience From a Single Tertiary Metabolic Center

Elif İşler‐Soylu 1,✉, Tanyel Zubarioglu 1, Esma Uygur 1, Tuğçe Aras‐Çöl 1, Hanım Babazade‐Aghakishili 1, Kağan Çalışgan 1, Ertuğrul Kıykım 1, Çiğdem Aktuğlu‐Zeybek 1
PMCID: PMC13406921  PMID: 42508972

ABSTRACT

Aim

Improved newborn screening and critical care allow more individuals with inherited metabolic disorders (IMDs) to survive to adulthood and reach reproductive age. However, given the rarity of these conditions, evidence on pregnancy management is limited and clinical practice is largely informed by case reports and expert opinions. This study aims to evaluate pregnancy outcomes and metabolic management strategies in women with IMDs, addressing a critical gap in evidence‐based care for this unique and growing patient population.

Methods

This retrospective, single‐center study included female patients aged 15–49 years with genetically confirmed IMDs who initiated treatment before conception and gave birth.

Results

Seven pregnancies in six women were included. The median maternal age at conception was 29.0 years and the median gestational age of infants was 38.4 weeks. In two patients with glutaric aciduria type I, individualized peripartum management protocols were successfully implemented. Enzyme replacement therapy was continued without complications throughout pregnancy in the woman with Gaucher disease. A previously unreported congenital heart defect was detected in the infant of a mother with tyrosinemia type II. Notably, one patient with 3‐Hydroxy‐3‐Methylglutaryl‐CoA Lyase Deficiency, whose first pregnancy ended in a healthy birth despite peripartum metabolic instability, experienced fatal metabolic decompensation following a miscarriage in her second pregnancy.

Conclusions

These findings indicate that while successful pregnancies are possible, severe maternal complications and fetal anomalies can still occur. These observations highlight the urgent need for structured adult care pathways and disease‐specific pregnancy management strategies as this population continues to grow.

Keywords: Glutaric acidemia type 1, gyrate atrophy, mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA Lyase deficiency, pregnancy, Tyrosinemia type II

1. Introduction

Inherited metabolic disorders (IMDs) were once considered exclusively pediatric conditions; however, expanded newborn screening programs, cascade screening, and advances in clinical management have enabled an increasing number of affected individuals to survive into adulthood [1]. As a result, two major challenges have emerged: ensuring a structured transition from pediatric to adult services and addressing the long‐term complications [2].

These challenges are particularly relevant for women, as pregnancy imposes substantial physiological and metabolic demands that may precipitate metabolic decompensation in several IMDs [3, 4]. Early gestation is predominantly anabolic, whereas late gestation is characterized by increasing insulin resistance, accelerated lipolysis and higher protein turnover. In this setting, fasting, hyperemesis, intercurrent illness or inadequate nutritional intake may trigger catabolism [5].

Pregnancy may affect a broad range of IMDs, particularly organic acidurias, fatty acid oxidation disorders, ketogenesis defects, and amino acid disorders, in which physiological adaptations may disrupt metabolic homeostasis. Diagnosis is based on biochemical investigations, including plasma amino acids, acylcarnitine profiling, urine organic acids, enzyme assays and molecular genetic testing [6].

Organic acidurias and ketogenesis defects, such as glutaric aciduria type I (GA‐I) and mitochondrial 3‐hydroxy‐3‐methylglutaryl‐CoA lyase deficiency (HMGCLD), are particularly vulnerable to catabolic stress and may present with hypoglycemia, hyperammonemia, metabolic acidosis, or secondary carnitine deficiency during pregnancy [7, 8]. These metabolic risks form the basis for disease‐specific management strategies, including avoidance of catabolism, adequate caloric intake, and carnitine supplementation. These risks necessitate disease‐specific management focused on preventing catabolism, maintaining adequate energy intake, and supplementing carnitine when indicated. Amino acid disorders, including tyrosinemia type II and ornithine aminotransferase (OAT) deficiency, require lifelong dietary and biochemical control, although the fetal consequences of persistent maternal amino acid imbalance remain poorly understood [9, 10]. In contrast, Gaucher disease is primarily associated with hematologic, visceral, and skeletal complications that may worsen during pregnancy [11, 12]. Collectively, these diverse metabolic risks require individualized surveillance, disease‐specific nutritional and pharmacologic management, and close multidisciplinary collaboration.

To date, pregnancy in IMDs has been most extensively studied in phenylketonuria (PKU) for which comprehensive guidelines are available [13]. In contrast, evidence for other IMDs remains sparse, with only scattered case reports addressing conditions such as urea cycle defects, organic acidemias, fatty acid oxidation disorders, glycogen storage diseases, and lysosomal storage disorders [14, 15, 16, 17, 18, 19]. Consequently, pregnancy management in these rare conditions remains largely experience‐based, and standardized protocols are lacking.

In this retrospective study, we aim to describe the clinical management of pregnancies in women with IMDs, focusing on metabolic protocols and associated maternal and neonatal outcomes. This will contribute to the limited existing literature and underscore the need for standardized guidelines, particularly during the transition from pediatric to adult care.

2. Materials and Methods

2.1. Study Design

This single‐center, retrospective observational study was conducted at the Department of Nutrition and Metabolism, Istanbul University‐Cerrahpaşa, Cerrahpaşa Faculty of Medicine, a tertiary care university hospital in İstanbul, Türkiye. The study covered the period from January 1, 2010 to December 31, 2025. Ethical approval for the study was obtained from the local ethics committee (approval number: 02.09.2025–1404935). Permission to use patient data for research and publication was granted by the institutional administration.

As there is no standard adult transition system for IMDs in our department, women with IMDs continue to be followed longitudinally in the Pediatric Metabolism Department. The metabolic team includes both metabolic consultants and dietitians. Pregnancy care was coordinated with the Obstetrics Department through an active consultation pathway, in which the metabolic team communicated a diagnosis‐specific management plan (including dietetic strategy, treatment adjustments when applicable and a biochemical monitoring approach) and maintained close communication via consultations throughout gestation. Peripartum planning was also coordinated with the Anesthesiology Department through case‐based consultations. In addition, the Neonatology team was routinely informed and involved in perinatal planning given the high‐risk nature of these pregnancies.

2.2. Participant Selection

Participants were selected from the institutional records of patients who were evaluated and followed at our center during the study period, according to predefined eligibility criteria.

2.2.1. Inclusion Criteria

Female patients were included if they met all the following criteria:

  • −

    Age between 15 and 49 years.

  • −

    Genetically confirmed diagnosis of an IMD

  • −

    Diagnosis established and disease‐specific medical and/or dietary treatment started before conception

  • −

    Pregnancy resulting in a live birth.

2.2.2. Exclusion Criteria

Patients were excluded if any of the following criteria were met:

  • −

    Incomplete medical records.

  • −

    Pregnancy occurring before IMD diagnosis or before the start of disease‐specific treatment.

  • −

    Diagnosis of an IMD for which pregnancy outcomes and management strategies are already well characterized in the literature (e.g., phenylketonuria, biotinidase deficiency). These disorders were excluded because the primary aim of the study was to evaluate pregnancy management in rare IMDs with limited published evidence and without widely established pregnancy‐specific management protocols.

  • −

    Diagnosis of an IMD that does not require disease‐specific medical or dietary treatment or specialized metabolic monitoring during pregnancy.

2.3. Data Collection

Clinical, biochemical, and obstetric data were obtained retrospectively from electronic medical records and external laboratory reports.

Maternal body weight and height were recorded at each clinical visit. Birth weight was recorded from the birth charts.

Biochemical parameters monitored included acylcarnitines (μmol/L), plasma amino acid profiles (μmol/L), blood gas indices (pH and bicarbonate, mmol/L), plasma ammonia (μmol/L), and glucose (mg/dL).

Pathogenic variants were identified by targeted Sanger sequencing in the institutional molecular genetics laboratory. Sequence variants were classified for pathogenicity in accordance with the 2015 guidelines of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP).

Nutritional status during pregnancy was assessed using a combination of anthropometric, biochemical, and dietary methods. Dietary intake was evaluated using 24‐h dietary recalls. Reported data were analyzed in relation to the Recommended Dietary Allowance (RDA) and FAO/WHO/UNU safe level of protein intake to determine the adequacy of energy and protein [20].

2.4. Statistical Analysis

Statistical analyses were performed using the Statistical Package for the Social Sciences (SPSS) version 31.0 (IBM Corp., Armonk, NY, USA). Descriptive statistics for continuous variables are presented as mean ± standard deviation (SD) for normally distributed data, or as median with interquartile range (IQR; 25th–75th percentiles) for non‐normally distributed data. Categorical variables are summarized as frequencies and percentages. Normality was assessed using the Shapiro–Wilk test.

3. Results

A total of 402 female patients aged 15–49 years who visited the Department of Metabolism during the study period were screened for eligibility. After stepwise exclusion overall, 6 women with a total of 7 pregnancies met the full inclusion criteria. The detailed screening and exclusion process is shown in Figure 1.

FIGURE 1.

FIGURE 1

Flowchart illustrating participant screening, exclusion process and final cohort selection.

3.1. Clinical, Demographic and Molecular Characteristics

The cohort comprised seven pregnancies in six women with molecularly confirmed IMDs. Genetic testing identified pathogenic or likely pathogenic variants. The underlying molecular diagnoses and baseline clinical characteristics of these patients are summarized in Table 1.

TABLE 1.

Molecular characterization and baseline phenotypic features of the study cohort.

ID Diagnosis Gene Nucleotide change Protein change Age at diagnosis (years) Baseline phenotype/key features
P01 Tyrosinemia type II TAT c.292A > T a p.(Lys98Ter) 16 Keratitis, cognitive impairment
P02 GA‐1 GCDH c.263G > A a p.(Arg88His) 23 Dizziness, asthenia; MRI with dentate/subthalamic hyperintensities
P03 GA‐1 GCDH c.[641C > T];[1204C > T] b p.[Thr214Met]; [Arg402Trp] 26 Myalgia, dizziness; Maternal low C0 identified via newborn screening
P04 Gaucher disease GBA1 c.[1226A > G];[637T > A] b p.[Asn370Ser]; [Phe213Ile] 17 Splenomegaly, osteopenia
P05 HMGCLD HMGCL c.31C > T a p.(Arg11Ter) 3 Neonatal hypoglycemia and high‐anion‐gap metabolic acidosis
P06 OAT deficiency OAT c.991C > T a p.(Arg33Ter) 10 Visual impairment, gyrate atrophy

Abbreviations: C0, free carnitine; GA‐1, glutaric aciduria type I; HMGCLD, HMG‐CoA lyase deficiency; MRI, magnetic resonance imaging; OAT, ornithine aminotransferase; P, patient.

a

Reported variants represent the disease‐causing genotype for each patient and are indicated as homozygous.

b

Reported variants represent the disease‐causing genotype for each patient and are indicated as compound heterozygous.

Overall, five of the six patients (83.3%) were managed with dietary interventions, including protein‐restricted diets for amino acid and organic acid disorders, and fat and protein‐restricted diets for ketone body metabolism disorders. Pharmacological treatment was tailored to the underlying IMD. Carnitine supplementation was administered to both patients with GA‐I and to the patient with HMGCLD, while riboflavin was prescribed for the patients with GA‐I. Enzyme replacement therapy was continued throughout pregnancy in the patient with Gaucher disease.

3.2. Metabolic Management, Course of Pregnancy Outcomes

During the pregnancies the metabolic team actively implemented disease‐specific protocols including individualized nutritional planning and serial biochemical monitoring. For the patient with Gaucher disease, antenatal care primarily involved monitoring Gaucher disease activity, such as hematological parameters and organ involvement, rather than the acute catabolic decompensation prevention strategies required for disorders of energy metabolism. At conception, the median maternal age was 29.0 years (26.0–31), and the median BMI was 25 kg/m2 (21.8–30). All pregnancies occurred spontaneously without fertility treatment.

The median gestational age at delivery was 38 weeks (38.0–39). The predominant mode of delivery was cesarean section in five cases (71.4%), while two women (28.6%) gave birth vaginally.

3.3. Neonatal Outcomes

The infant's median birth weight was 3300 g (3140–3450). No macrosomic infants or infants born small for gestational age were recorded. A major structural anomaly was detected prenatally in the newborn of the mother with tyrosinemia type II. Expanded newborn screening using tandem mass spectrometry was unremarkable in seven infants. Transient, self‐resolving acylcarnitine elevations were observed in the newborn of the mother with HMGCLD. Data on obstetric details, metabolic interventions and corresponding neonatal screening results are presented in Table 2.

TABLE 2.

Obstetric characteristics, peripartum metabolic management and neonatal outcomes for each pregnancy.

ID Diagnosis Pregnancy Pregnancy age (years) Pregnancy outcome Gestational week Delivery method Birth weight (g) Therapy at conception Diet during pregnancy Peripartum metabolic protocol Neonatal findings
P01 Tyrosinemia type II 1–1 29 Live birth 38 + 0 C/S 2600 Protein restricted — CHD, normal tyrosine level
P02 GA‐1 2–1 26 Live birth 38 + 0 Vaginal 3700 LC, B2 Protein restricted IV dextrose, IV Carnitine No low C0; no C5DC elevation
P03 GA‐1 3–1 30 Live birth 39 + 3 C/S 3140 LC, B2 Protein restricted IV dextrose, IV Carnitine C0 normal; no C5DC elevation
P04 Gaucher disease 4–1 28 Live birth 36 + 0 C/S 3180 ERT No — —
4–2 32 Live birth 38 + 0 C/S 3450 ERT No — —
P05 HMGCLD 5–1 21 Live birth 39 + 0 C/S 3335 LC Fat and protein restricted IV dextrose, IV Carnitine Transient acylcarnitine elevations normal by 15d
5–2 a 29 Spontaneous abortion
P06 OAT deficiency 6–1 31 Live birth 38 + 5 Vaginal 3300 Cre, B6, E Protein restricted — —

Abbreviations: B2, riboflavin; B6, pyridoxine; CHD, congenital heart disease; Cre, creatinine; C/S, cesarean section; C0, free carnitine; C5DC, glutarylcarnitine; E: vitamin E; ERT, enzyme replacement therapy; GA‐1, glutaric aciduria type I; HMGCLD, HMG‐CoA lyase deficiency; IV, intravenous; LC, L‐carnitine; OAT, ornithine aminotransferase.

a

Resulted in fatal maternal metabolic decompensation following a missed abortion.

3.4. Case Presentations

3.4.1. Patient 01: Tyrosinemia Type II

A 27‐year‐old woman with tyrosinemia type II became unintentionally pregnant. She was diagnosed at age 16 after developing corneal lesions and markedly elevated plasma tyrosine levels. Although a tyrosine‐ and phenylalanine‐restricted diet was initiated, long‐term metabolic control remained suboptimal.

The patient's protein intake during the preconception period was 1.2 g/kg/day, with 0.5 g/kg/day from a tyrosine‐ and phenylalanine‐free amino acid mixture (TYR‐AA mixture) and 0.7 g/kg/day from natural protein. No increase in protein intake was made during the first trimester. However, dietary records showed an average intake of 0.3 g/kg/day from the TYR‐AA mixture and 0.7 g/kg/day from natural protein sources. In the second and third trimesters the recommended protein distribution was 0.8 g/kg/day from the TYR‐AA mixture and 0.6 g/kg/day from natural protein. However, the patient had difficulty consuming the TYR‐AA mixture as prescribed and dietary adherence remained suboptimal throughout pregnancy.

At conception, pre‐pregnancy tyrosine levels were 828 μmol/L. Dietary adherence was inconsistent throughout pregnancy and plasma tyrosine concentrations fluctuated between 564 to 847 μmol/L. Natural protein intake, amino acid supplementation, and corresponding plasma tyrosine levels by trimester are shown in Figure 2.

FIGURE 2.

FIGURE 2

Natural protein intake, tyrosine‐ and phenylalanine‐free amino acid mixture (TYR mixture) supplementation and plasma tyrosine concentrations across different trimesters of pregnancy in a patient with tyrosinemia type II (Patient 01). Stacked bars represent daily protein intake from natural protein sources and the TYR mixture (g/kg/day). The red line indicates plasma tyrosine concentrations (μmol/L) measured during the preconception period, each trimester and postpartum follow‐up.

At 30 weeks, fetal echocardiography revealed multiple structural cardiac abnormalities, including an overriding aorta, a perimembranous ventricular septal defect, a secundum atrial septal defect, and a small patent ductus arteriosus. These findings occurred in the context of persistently poor metabolic control during both the preconception and gestational periods. Uncomplicated elective cesarean section performed on maternal request. Postnatal echocardiography confirmed the cardiac lesions.

3.4.2. Patient 02: Glutaric Aciduria Type I

A 23‐year‐old woman with GA‐I had an unplanned pregnancy. She had no history of encephalopathic crises, and her two prior pregnancies (before diagnosis) were uncomplicated. Preconception treatment included L‐carnitine (1 g/day) and riboflavin (100 mg twice daily), with no dietary lysine restriction.

The first trimester was clinically stable; her carnitine supplementation was increased from 1 g to 1.5 g daily in the third trimester due to persistently low plasma carnitine levels. C5DC rose slightly toward the end of pregnancy, consistent with increasing catabolic demand. Serial carnitine and acylcarnitine profiles are shown in Figure 3A.

FIGURE 3.

FIGURE 3

Longitudinal biochemical profiles and dietary intake during pregnancy in two patients with glutaric aciduria type I. (A) Patient 02: Serial plasma glutarylcarnitine (C5DC), free carnitine (C0) and lysine concentrations measured from the preconception period through pregnancy and postpartum follow‐up (upper panel), along with longitudinal dietary protein intake (g/kg/day) and total caloric intake (kcal/day) (lower panel). (B) Patient 04: Serial plasma C5DC, C0 and lysine concentrations throughout pregnancy (upper panel), with corresponding dietary protein intake (g/kg/day) and total caloric intake (kcal/day) during gestation (lower panel).

A multidisciplinary pre‐delivery plan was developed in collaboration with the anesthesia and obstetrics teams. To minimize preoperative fasting, her cesarean section was scheduled as the first case of the day. Peripartum management included continuous intravenous dextrose with electrolytes (glucose infusion rate 3–4 mg/kg/min) at 1.5 times maintenance, plus 2 g intravenous L‐carnitine. She gave birth vaginally under epidural anesthesia. Intravenous glucose was continued until adequate oral intake was established. Maternal biochemical parameters normalized within days.

3.4.3. Patient 03: Glutaric Aciduria Type I

A 30‐year‐old woman with GA‐I became pregnant spontaneously. The diagnosis was made after low C0 levels detected in the newborn screening of her previous child, prompting maternal evaluation. Preconception treatment included L‐carnitine (1 g/day) and riboflavin (100 mg twice daily), without dietary lysine restriction.

During pregnancy, she continued an unrestricted diet with caloric intake adjusted to gestational requirements. Figure 3B summarizes her serial acylcarnitine profiles and dietary regimen.

Delivery was performed according to a metabolic protocol that included avoidance of fasting, continuous intravenous dextrose (glucose infusion rate 3–4 mg/kg/min) and intravenous L‐carnitine supplementation (2 g). At 39 + 3 weeks, she gave birth to a healthy infant by cesarean section due to a previous cesarean section history. Neonatal tandem mass spectrometry screening was normal.

3.4.4. Patient 04: Gaucher Disease

A woman with Gaucher disease was diagnosed at age 17 after evaluation for hepatosplenomegaly and bone pain. She received imiglucerase at 100 U/kg due to osteonecrosis of the left femoral head.

At age 28, she became pregnant, and enzyme replacement therapy was maintained at the same dose throughout the pregnancy. Blood pressure remained normal. Bone pain crises occurred during pregnancy. However, analgesics—particularly nonsteroidal anti‐inflammatory drugs—were avoided whenever possible. Hematologic parameters remained stable, with a median of hemoglobin 11.6 g/dL (11.4–11.65 g/dL) and a median platelet count of 134 × 103/μL (124–150 × 103/μL). Otherwise, the pregnancy was uneventful. At 36 + 0 weeks, she presented in spontaneous preterm labor. Given maternal femoral head osteonecrosis and associated mobility/positioning concerns, birth was completed by cesarean section.

Bone pain persisted in the postpartum period. She experienced a second uncomplicated pregnancy at age 31 by C/S delivery, again characterized by increased bone pain but no systemic complications.

3.4.5. Patient 05: Mitochondrial 3‐Hydroxy‐3‐Methylglutaryl‐CoA Lyase Deficiency

A 21‐year‐old woman with HMGCLD became pregnant spontaneously. The initial diagnosis was made in the neonatal period following an episode of severe hypoglycemia and metabolic acidosis. Long‐term treatment included L‐carnitine (1 g/day), dietary protein and fat restriction.

At conception, L‐carnitine was increased to 1.5 g/day, and a diet was prescribed as 2000 kcal/day, 0.5 g/kg/day protein and 35 mg/kg/day leucine. Dietary adherence was suboptimal across all trimesters; however, venous blood gases remained low‐normal, with minimal lactate accumulation in the first and second trimesters. Free carnitine progressively decreased despite increased L‐carnitine dosing (1.5–2 g/day).

She gave birth at 39 weeks by elective cesarean section to facilitate controlled peripartum metabolic management and minimize fasting/catabolic stress. Peripartum care with dextrose (at a glucose infusion rate of 3–4 mg/kg/min) and intravenous L‐carnitine (2 g) were performed. At the onset of labor, mild metabolic acidemia occurred with hypoglycemia and hyperammonemia, all resolved within 24 h with glucose and carnitine therapy. A healthy infant was born. On day 1, the newborn's acylcarnitine profile showed elevated levels (C0: 229 μmol/L; C2: 81.1 μmol/L; C5‐OH: 0.84 μmol/L), attributed to intrapartum carnitine administration. By day 15, these values had normalized. Biochemical parameters and changes in the acylcarnitine profile during pregnancy, peripartum, and the postpartum period are shown in Figure 4A,B.

FIGURE 4.

FIGURE 4

Metabolic monitoring during pregnancy and postpartum follow‐up in a patient with HMGCLD (Patient 05). (A) Serial measurements of blood pH, plasma ammonia and blood glucose concentrations throughout pregnancy, the peripartum period and postpartum follow‐up. Peripartum monitoring showed transient hyperammonemia accompanied by mild metabolic acidemia and hypoglycemia, which improved during the postpartum period. (B) Longitudinal acylcarnitine profile showing plasma 3‐hydroxyisovalerylcarnitine (C5OH), adipoylcarnitine (C6DC) and free carnitine (C0) concentrations during pregnancy and postpartum follow‐up.

At age 29 she presented with vaginal bleeding at 5 weeks of gestation, where she was diagnosed with a missed abortion and underwent urgent curettage under general anesthesia. Postoperatively, the patient became lethargic. Arterial blood gas analysis showed a pH of 7.11, pCO2 of 6.8 mmHg, and HCO3 − of 6.8 mmol/L, with a base excess of −27.3. Serum lactate was 12.35 mmol/L, and plasma ammonia was 485 μmol/L; glucose was below the detectable limit. She was admitted to the intensive care unit. High‐dextrose fluids and intravenous L‐carnitine were administered. Due to hyperammonemia, acute kidney injury and signs of hepatic failure, continuous renal replacement therapy was initiated. During follow‐up, she developed multi‐organ failure requiring ongoing hemodynamic support. Despite intensive metabolic and supportive management, she died secondary to multi‐organ failure.

3.4.6. Patient 06: Ornithine Aminotransferase (OAT) Deficiency

A 29‐year‐old woman, diagnosed with retinal atrophy at age 10, became spontaneously pregnant. Pyridoxine (300 mg/day), creatine (100 mg/kg/day), vitamin E (100 mg/day), and a protein‐restricted diet were started. Initial pregnancy dietary records showed 1500 kcal/day and 0.5 g/kg/day protein intake. Second‐trimester energy and protein intakes were 1800 kcal/day and 0.6 g/kg/day, respectively. In the third trimester, protein intake stayed at 0.6 g/kg/day, and energy intake increased to 1950 kcal/day.

Due to COVID‐19 lockdowns, she was unable to attend in‐person clinic visits; however, she strictly adhered to the prescribed diet throughout pregnancy. During pregnancy, plasma ornithine levels ranged from 487.8 to 705.2 μmol/L. Serial plasma levels of ornithine before and during pregnancy are summarized in Supporting Information S1.

She gave birth to a healthy infant by vaginal delivery. The neonatal amino acid analysis on day 15 was normal.

4. Discussion

This retrospective case series describes a multidisciplinary approach to pregnancy surveillance and peripartum/postpartum management in women with IMDs, addressing an area where published evidence remains limited. Because these disorders are rare, current knowledge derives largely from isolated case reports, and practical aspects of longitudinal metabolic monitoring and peripartum management remain incompletely described. As a result, pregnancy care is often individualized rather than guided by standardized disease‐specific recommendations. In this context, we present our experience with individualized biochemical surveillance, nutritional and pharmacological interventions and anticipatory peripartum management across seven pregnancies complicated by diverse IMDs. Among pregnancies resulting in live birth, several were completed without major acute maternal metabolic complications. However, clinically significant maternal and neonatal adverse outcomes were also observed, including congenital cardiac anomalies in the infant of a mother with tyrosinemia type II and fatal metabolic decompensation following a missed abortion in a patient with HMGCLD. Overall, our findings suggest that favorable pregnancy outcomes may be achieved in selected women with IMDs through individualized metabolic surveillance, structured peripartum planning and coordinated multidisciplinary care.

Pregnancy is accompanied by profound physiological adaptations, including increased energy expenditure, altered lipid and amino acid metabolism and progressive catabolism during late gestation, labor and the postpartum period [5, 17]. These changes may increase the risk of metabolic instability in women with disorders affecting intermediary metabolism, particularly when compounded by fasting, hyperemesis, intercurrent illness or obstetric interventions [21, 22]. Our observations, together with previous reports, emphasize the importance of maintaining adequate caloric support and minimizing catabolic stress throughout pregnancy and during both elective and emergency obstetric procedures. In addition, although some IMDs are not typically associated with acute maternal metabolic crises, the potential fetal effects of persistent maternal metabolite accumulation remain incompletely understood. Because several metabolites cross the placenta, continued attention to possible teratogenic and neurodevelopmental consequences is warranted, as illustrated by maternal PKU and suggested by maternal tyrosinemia [9, 23].

All women in our cohort underwent preconception counseling, which included discussion of inheritance patterns, reproductive options and the anticipated metabolic and nutritional challenges of pregnancy. Because many IMDs follow an autosomal recessive inheritance pattern, counseling also provided an opportunity to discuss recurrence risk, carrier testing and reproductive planning, thereby supporting informed decision‐making [24].

In both GA‐I and HMGCLD, pregnancy management included serial monitoring of free carnitine and acylcarnitine profiles, with L‐carnitine supplementation adjusted according to biochemical findings. In these disorders, accumulating acyl‐CoA intermediates are conjugated with carnitine and excreted as acylcarnitines, predisposing patients to secondary free carnitine depletion that may be exacerbated during pregnancy. In our cohort, dose adjustments were accompanied by sustained biochemical stability throughout gestation and may have helped accommodate the increasing metabolic demands of late pregnancy. These observations are consistent with current recommendations advocating regular biochemical monitoring and individualized carnitine supplementation during pregnancy [21].

The clinical course of the patient with HMGCLD demonstrates the marked variability that can occur during pregnancy in this disorder. Her first pregnancy was successfully managed with proactive metabolic support, whereas a subsequent pregnancy ended in fatal metabolic decompensation after a missed abortion requiring surgical curettage under general anesthesia. Successful pregnancies in women with HMGCLD have previously been reported when catabolic stress was anticipated and managed with intensive glucose support and L‐carnitine supplementation during the peripartum period [7, 22, 25]. In contrast, Langendonk et al. [17] described a similar fatal outcome following abortion‐related metabolic decompensation. Although conclusions cannot be drawn from individual cases, these observations underscore the need for careful emergency planning and perioperative metabolic management in women with HMGCLD, including after pregnancy loss. Similarly, late‐gestation rises in C5DC among patients with GA‐I signaled heightened catabolic pressure; responding with L‐carnitine escalation provides support for recommendations previously advanced in the literature [2, 21]. Pregnancy experience in women with GA‐I is limited to a small number of case reports and case series. Stepien et al. [2] described two successful pregnancies in a woman with GA‐I who was managed with a lysine‐ and tryptophan‐free amino acid mixture along with synthetic energy supplementation to meet the increased caloric demands of pregnancy. Natural protein intake was more restricted than in our patients. Current management recommendations for GA‐I acknowledge that the role of lysine‐ and tryptophan‐free amino acid mixtures in adulthood remains uncertain and should be individualized according to clinical and biochemical status [8]. Both women in our cohort had late‐onset GA‐I and remained clinically and biochemically stable with moderate natural protein restriction and close metabolic surveillance; therefore, additional amino acid mixture supplementation was not considered necessary during pregnancy. Our experience is consistent with current recommendations supporting individualized dietary management in adults with GA‐I rather than routine amino acid mixture supplementation.

Beyond the risk of maternal metabolic decompensation, pregnancy in some IMDs raises concerns about fetal exposure to accumulated metabolites. While the teratogenicity of maternal PKU is well established, comparable evidence for maternal hypertyrosinemia remains limited [26]. In our cohort, a complex congenital cardiac defect was identified in the infant of a mother with tyrosinemia type II who had persistently elevated plasma tyrosine concentrations throughout pregnancy. Although tyrosine toxicity is well recognized in ocular and neurological tissues, its role in fetal cardiac development has not previously been described [27]. Given the background prevalence of congenital heart disease, causality cannot be inferred from this single observation; however, it raises a hypothesis that warrants further investigation [28]. A successful pregnancy has previously been reported in a woman with tyrosinemia type II who maintained maternal plasma tyrosine concentrations below 200 μmol/L through strict dietary restriction and supplementation with a phenylalanine‐ and tyrosine‐free amino acid mixture [29]. In contrast, maternal tyrosine concentrations in our patient remained persistently above 500 μmol/L because of suboptimal dietary adherence. Severe neurodevelopmental impairment has also been reported in the offspring of a mother with markedly uncontrolled maternal hypertyrosinemia, with tyrosine concentrations approaching 1700 μmol/L during pregnancy. The affected child developed microcephaly, intellectual disability, maxillary hypoplasia and seizures [9]. Taken together, these observations suggest that sustained maternal hypertyrosinemia may warrant careful metabolic control during pregnancy, although the spectrum of fetal effects remains insufficiently defined.

Pregnancy in women with OAT deficiency has rarely been reported. An uncomplicated pregnancy was previously described under close dietary supervision and regular biochemical monitoring, with strict protein restriction and supplementation using an ornithine‐restricted amino acid mixture to maintain plasma ornithine concentrations below 500 μmol/L [30]. Our patient was managed with a protein‐restricted diet without amino acid mixture supplementation and maintained a median plasma ornithine concentration of 424 μmol/L throughout pregnancy. Previous reports have also emphasized the importance of avoiding arginine deficiency during ornithine restriction because of its potential association with pregnancy‐related complications such as preeclampsia [30]. No such complication occurred in our patient. Although the available evidence remains limited, both published reports and our findings indicate that careful dietary management with regular biochemical monitoring may support favorable pregnancy outcomes in selected patients with OAT deficiency. In contrast, Raja et al. [31] reported recurrent pregnancy loss in another patient with OAT deficiency, illustrating the variability of pregnancy outcomes. Our patient's stable metabolic control despite COVID‐19‐related restrictions further suggests that individualized follow‐up strategies may remain feasible when conventional clinic visits are interrupted.

Planned cesarean section was performed in several pregnancies consistent with previous reports [22, 23]. However, delivery mode in our cohort was determined based on obstetric and metabolic indications rather than diagnosis alone. Two women had uncomplicated vaginal deliveries, indicating that vaginal birth may be an appropriate option in carefully selected and closely monitored pregnancies. Our experience with Gaucher disease is consistent with previous reports supporting continuation of enzyme replacement therapy throughout pregnancy [18, 32]. Although our patient required high dose imiglucerase because of skeletal involvement, treatment was maintained without major systemic complications and hematological parameters remained stable. Exacerbation of bone pain during pregnancy was observed, consistent with the underlying skeletal disease and increased gestational mechanical load [33].

Key strengths of this study include case‐level documentation of individualized management from preconception through peripartum and postpartum period, with serial biochemical and dietary data that are directly applicable to clinical practice. However, this study also has several limitations. First, the sample size was small, reflecting both the rarity of the included disorders and the strict inclusion criteria requiring genetically confirmed diagnoses and longitudinal pregnancy follow‐up. The cohort was clinically heterogeneous, comprising disorders with distinct metabolic pathways, disease mechanisms, and pregnancy‐related risks, which limits direct comparison between cases. The single‐center retrospective design may limit generalizability to other populations and clinical settings. In addition, retrospective data collection resulted in variability in the frequency of biochemical monitoring and completeness of longitudinal clinical data across patients. Selection bias should also be acknowledged, as we intentionally focused on IMDs for which pregnancy management is less well characterized and excluded disorders with established pregnancy protocols, such as PKU. Consequently, the findings should be interpreted as descriptive clinical observations rather than generalizable estimates of maternal or neonatal risk. Larger multicenter prospective studies and international registries are needed to better define disease‐specific pregnancy outcomes and establish standardized management strategies.

In conclusion, pregnancy in women with IMDs is no longer an exception but a manageable clinical scenario when guided by risk‐adapted protocols, proactive peripartum planning, and coordinated multidisciplinary care. Future work should prioritize multicenter, prospective international registries designed to capture disease‐specific maternal and neonatal outcomes and to evaluate standardized management algorithms.

Author Contributions

E.İ.‐S.: conceptualization, formal analysis, investigation, resources, writing – original draft, visualization. T.Z.: conceptualization, methodology, validation, data curation, writing – review and editing, supervision, project administration. E.U.: investigation, resources. T.A.‐Ç.: investigation, resources. H.B.‐A.: investigation, resources. K.Ç.: investigation, resources. E.K.: writing – review and editing, supervision, project administration. Ç.A.‐Z.: writing – review and editing, supervision, project administration.

Funding

The authors have nothing to report.

Ethics Statement

This study was performed in accordance with the Declaration of Helsinki and was approved by the Local Ethics Committee of Istanbul University‐Cerrahpaşa, Cerrahpaşa Faculty of Medicine (approval no: 02.09.2025–1404935).

Consent

Informed consent was received from all participants.

Conflicts of Interest

The authors declare no conflicts of interest.

Supporting information

Supporting Information: S1: Serial plasma levels of ornithine before and during pregnancy of OAT Deficiency patient.

JOG-52-0-s001.pdf (103.5KB, pdf)

İşler‐Soylu E., Zubarioglu T., Uygur E., et al., “Managing Pregnancy in Inherited Metabolic Disorders: Experience From a Single Tertiary Metabolic Center,” Journal of Obstetrics and Gynaecology Research 52, no. 8 (2026): e70419, 10.1111/jog.70419.

A preliminary version of this study was presented as an oral presentation at the 2nd National Pediatric Nutrition Congress of the Turkish Pediatric Nutrition and Metabolism Association, held in Trabzon, Türkiye, on November 6–9, 2025.

Data Availability Statement

The datasets generated during the current study are not publicly available. Given the small cohort size and the rare nature of the underlying inherited metabolic disorders, the risk of re‐identification cannot be fully excluded despite de‐identification efforts. Additionally, sharing individual‐level data was not covered by the ethics committee approval and is restricted by institutional regulations and applicable data protection laws. Aggregated data supporting the findings are presented within the article and its tables. Further inquiries regarding data access may be directed to the corresponding author, subject to institutional review and compliance with ethical and legal requirements.

References

  • 1. Sirrs S., Hollak C., Merkel M., et al., “The Frequencies of Different Inborn Errors of Metabolism in Adult Metabolic Centres: Report From the SSIEM Adult Metabolic Physicians Group,” JIMD Reports 27 (2015): 85, 10.1007/8904_2015_435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Stepien K. M., Pastores G. M., Hendroff U., et al., “Two Uneventful Pregnancies in a Woman With Glutaric Aciduria Type 1,” JIMD Reports 41 (2018): 29, 10.1007/8904_2017_81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Wilcox G., “Impact of Pregnancy on Inborn Errors of Metabolism,” Reviews in Endocrine & Metabolic Disorders 19, no. 1 (2018): 13, 10.1007/S11154-018-9455-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Thakur G., Shankar H., Arora T. K., and Kulkarni B., “Role of Mineral Nutrients Other Than Iron in Pregnancy: Under Recognized Opportunities to Improve Maternal/Fetal Outcomes: A Literature Review,” Archives of Gynecology and Obstetrics 309, no. 3 (2023): 895–905, 10.1007/s00404-023-07183-6. [DOI] [PubMed] [Google Scholar]
  • 5. Lain K. Y. and Catalano P. M., “Metabolic Changes in Pregnancy,” Clinical Obstetrics and Gynecology 50, no. 4 (2007): 938–948, 10.1097/GRF.0b013e31815a5494. [DOI] [PubMed] [Google Scholar]
  • 6. Stepien K. M., Langendonk J. G., Dao M., et al., “The Management and Clinical Outcomes of Pregnancies in Women With Urea Cycle Disorders: A Review of the Literature and Results of an International Survey,” Journal of Inherited Metabolic Disease 47, no. 6 (2024): 1239–1259, 10.1002/JIMD.12695;PAGE:STRING:ARTICLE/CHAPTER. [DOI] [PubMed] [Google Scholar]
  • 7. Santosa D., Donner M. G., vom Dahl S., et al., “Favourable Outcome in Two Pregnancies in a Patient With 3‐Hydroxy‐3‐Methylglutaryl‐CoA Lyase Deficiency,” JIMD Reports 37 (2017): 1–5, 10.1007/8904_2017_7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Boy N., Mühlhausen C., Maier E. M., et al., “Proposed Recommendations for Diagnosing and Managing Individuals With Glutaric Aciduria Type I: Second Revision,” Journal of Inherited Metabolic Disease 40, no. 1 (2017): 75–101, 10.1007/s10545-016-9999-9. [DOI] [PubMed] [Google Scholar]
  • 9. Cerone R., Fantasia A. R., Castellano E., Moresco L., Schiaffino M. C., and Gatti R., “Pregnancy and Tyrosinaemia Type II,” Journal of Inherited Metabolic Disease 25, no. 4 (2002): 317–318, 10.1023/A:1016558510123. [DOI] [PubMed] [Google Scholar]
  • 10. Ginguay A., Cynober L., Curis E., and Nicolis I., “Ornithine Aminotransferase, an Important Glutamate‐Metabolizing Enzyme at the Crossroads of Multiple Metabolic Pathways,” Biology 6, no. 1 (2017): 18, 10.3390/biology6010018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Belmatoug N., Di Rocco M., Fraga C., et al., “Management and Monitoring Recommendations for the Use of Eliglustat in Adults With Type 1 Gaucher Disease in Europe,” European Journal of Internal Medicine 37 (2017): 25–32, 10.1016/j.ejim.2016.07.011. [DOI] [PubMed] [Google Scholar]
  • 12. Rosenbaum H., “Management of Women With Gaucher Disease in the Reproductive Age,” Thrombosis Research 135, no. Suppl 1 (2015): S49–S51, 10.1016/S0049-3848(15)50443-X. [DOI] [PubMed] [Google Scholar]
  • 13. van Wegberg A. M. J., MacDonald A., Ahring K., et al., “European Guidelines on Diagnosis and Treatment of Phenylketonuria: First Revision,” Molecular Genetics and Metabolism 145, no. 2 (2025): 109125, 10.1016/J.YMGME.2025.109125. [DOI] [PubMed] [Google Scholar]
  • 14. Jafari P., Braissant O., Bonafé L., and Ballhausen D., “The Unsolved Puzzle of Neuropathogenesis in Glutaric Aciduria Type I,” Molecular Genetics and Metabolism 104, no. 4 (2011): 425–437, 10.1016/j.ymgme.2011.08.027. [DOI] [PubMed] [Google Scholar]
  • 15. Gillman B. A., Corcoran E., Mcnulty J., et al., “Organic Aciduria Disorders in Pregnancy: An Overview of Metabolic Considerations,” Metabolites 13, no. 4 (2023): 518, 10.3390/METABO13040518. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Jamerson P. A., “The Association Between Acute Fatty Liver of Pregnancy and Fatty Acid Oxidation Disorders,” Journal of Obstetric, Gynecologic, and Neonatal Nursing 34, no. 1 (2005): 87–92, 10.1177/0884217504272800. [DOI] [PubMed] [Google Scholar]
  • 17. Langendonk J. G., Roos J. C. P., Angus L., et al., “A Series of Pregnancies in Women With Inherited Metabolic Disease,” Journal of Inherited Metabolic Disease 35, no. 3 (2012): 419–424, 10.1007/S10545-011-9389-2. [DOI] [PubMed] [Google Scholar]
  • 18. Granovsky‐Grisaru S., Belmatoug N., Vom Dahl S., Mengel E., Morris E., and Zimran A., “The Management of Pregnancy in Gaucher Disease,” European Journal of Obstetrics, Gynecology, and Reproductive Biology 156, no. 1 (2011): 3–8, 10.1016/j.ejogrb.2010.12.024. [DOI] [PubMed] [Google Scholar]
  • 19. Grünert S. C., Rosenbaum‐Fabian S., Hannibal L., Schumann A., and Spiekerkötter U., “Three Successful Pregnancies in a Patient With Glycogen Storage Disease Type 0,” JIMD Reports 57, no. 1 (2021): 38–43, 10.1002/jmd2.12178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Trumbo P., Schlicker S., Yates A. A., and Poos M., “Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein and Amino Acids,” Journal of the American Dietetic Association 102, no. 11 (2002): 1621–1630, 10.1016/S0002-8223(02)90346-9. [DOI] [PubMed] [Google Scholar]
  • 21. Ituk U. S., Allen T. K., and Habib A. S., “The Peripartum Management of a Patient With Glutaric Aciduria Type 1,” Journal of Clinical Anesthesia 25, no. 2 (2013): 141–145, 10.1016/J.JCLINANE.2012.06.023. [DOI] [PubMed] [Google Scholar]
  • 22. Pipitone A., Raval D. B., Duis J., et al., “The Management of Pregnancy and Delivery in 3‐Hydroxy‐3‐Methylglutaryl‐CoA Lyase Deficiency,” American Journal of Medical Genetics. Part A 170, no. 6 (2016): 1600–1602, 10.1002/AJMG.A.37620. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Murphy E., “Pregnancy in Women With Inherited Metabolic Disease,” Obstetric Medicine 8, no. 2 (2015): 61–67, 10.1177/1753495X15576442. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Lu J., Chen J., Mei L., et al., “Clinical Application of Expanded Carrier Screening Based on Next‐Generation Sequencing in the Chinese Population,” Archives of Gynecology and Obstetrics 312, no. 3 (2025): 949–957, 10.1007/s00404-025-08100-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Sulaiman R. A., Al‐Nemer M., Khan R., Almasned M., Handoum B. S., and Al‐Hassnan Z. N., “Successful Management of Pregnancies in Patients With Inherited Disorders of Ketone Body Metabolism,” JIMD Reports 38 (2018): 41–44, 10.1007/8904_2017_24. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Saal H. M., Braddock S. R., Bull M. J., et al., “Maternal Phenylketonuria,” Pediatrics 122, no. 2 (2008): 445–449, 10.1542/PEDS.2008-1485. [DOI] [Google Scholar]
  • 27. Fois A., Borgogni P., Cioni M., et al., “Presentation of the Data of the Italian Registry for Oculocutaneous Tyrosinaemia,” Journal of Inherited Metabolic Disease 9, no. 2 Supplement (1986): 262–264, 10.1007/BF01799723. [DOI] [Google Scholar]
  • 28. Piemonti L., Vettor L., Balducci A., Farina A., and Contro E., “Assisted Reproductive Technology and the Risk of Fetal Congenital Heart Disease: Insights From a Tertiary‐Care Referral Center,” Archives of Gynecology and Obstetrics 310, no. 4 (2024): 2073–2080, 10.1007/s00404-024-07669-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Francis D. E. M., Kirby D. M., and Thompson G. N., “Maternal Tyrosinaemia II: Management and Successful Outcome,” European Journal of Pediatrics 151, no. 3 (1992): 196–199, 10.1007/BF01954383/METRICS. [DOI] [PubMed] [Google Scholar]
  • 30. Kanninen T., Bryant E., Koerner C., and Gonik B., “First Reported Case of Pregnancy in a Patient With Ornithine Aminotransferase Deficiency,” Nutrition 1 (2022): 93, 10.1016/j.nut.2021.111513. [DOI] [PubMed] [Google Scholar]
  • 31. Raja A. M., Janti S., Chendilnathan C. C., and Matheen A., “Scholars Journal of Medical Case Reports ISSN 2347‐9507 (Print) Rare Presentation of Gyrate Atrophy in Pregnancy,” Scholars Journal of Medical Case Reports 2, no. 9 (2014): 618–621, 10.36347/sjmcr.2014.v02i09.013. [DOI] [Google Scholar]
  • 32. Aladag H. and Aladag M., “Nine Healthy Deliveries in Four Pregnant Women With Enzyme Replacement Therapy in Gaucher Disease,” Annals of Medical Research 30, no. 2 (2023): 278–281. [Google Scholar]
  • 33. del Meijon‐Ortigueira M., Solares I., Muñoz‐Delgado C., et al., “Women With Gaucher Disease,” Biomedicine 12, no. 3 (2024): 579, 10.3390/BIOMEDICINES12030579. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information: S1: Serial plasma levels of ornithine before and during pregnancy of OAT Deficiency patient.

JOG-52-0-s001.pdf (103.5KB, pdf)

Data Availability Statement

The datasets generated during the current study are not publicly available. Given the small cohort size and the rare nature of the underlying inherited metabolic disorders, the risk of re‐identification cannot be fully excluded despite de‐identification efforts. Additionally, sharing individual‐level data was not covered by the ethics committee approval and is restricted by institutional regulations and applicable data protection laws. Aggregated data supporting the findings are presented within the article and its tables. Further inquiries regarding data access may be directed to the corresponding author, subject to institutional review and compliance with ethical and legal requirements.


Articles from The Journal of Obstetrics and Gynaecology Research are provided here courtesy of Wiley

RESOURCES